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ABSTRACT
Purpose Biodegradable polymeric nanoparticles of different
architectures based on polyethylene glycol-co-poly(ε-
caprolactone) block copolymers have been loaded with
noscapine (NOS) to study their effect on its anticancer activity.
It was intended to use solubility of NOS in an acidic environ-
ment and ability of the nanoparticles to passively target drugs
into cancer tissue to modify the NOS pharmacokinetic prop-
erties and reduce the requirement for frequent injections.
Methods Linear and star-shaped copolymers were
synthetized and used to formulate NOS loaded nanoparticles.
Cytotoxicity was performed using a sulforhodamine Bmethod
on MCF-7 cells, while biocompatibility was determined on
rats followed by hematological and histopathological
investigations.
Results Formulae with the smallest particle sizes and ade-
quate entrapment efficiency revealed that NOS loaded nano-
particles showed higher extent of release at pH 4.5. Colloidal
stability suggested that nanoparticles would be stable in blood
when injected into the systemic circulation. Loaded nanopar-
ticles had IC50 values lower than free drug. Hematological
and histopathological studies showed no difference between
treated and control groups. Pharmacokinetic analysis revealed
that formulation P1 had a prolonged half-life and better bio-
availability compared to drug solution.
Conclusions Formulation of NOS into biodegradable poly-
meric nanoparticles has increased its efficacy and residence on
cancer cells while passively avoiding normal body tissues.
KEY WORDS noscapine . passive targeting . pHdependent
release . polyethylene glycol-co-poly(ε-caprolactone)
(PEG-co-PCL) . polymeric nanoparticles
ABBREVIATIONS
AFM Atomic force microscopy
CMC Critical micelle concentration
DLS Dynamic light scattering
HPLC High performance liquid chromatography
NOS Noscapine
NPs Nanoparticles
PEG-co-PCL Polyethylene glycol-co-poly(ε-caprolactone)
block copolymers
PLA Poly(lactic acid)
PLGA Poly(lactide-co-glycolide)
RES Reticuloendothelial system
SRB Sulphorhodamine-B
INTRODUCTION
Therapeutic strategies for most cancers, including breast can-
cer, currently involve a combination of surgery, radiotherapy,
immunotherapy, hormone therapy and/or chemotherapy.
The efficacy of a therapeutic formulation depends on its abil-
ity to selectively target diseased tissue, overcome biological
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barriers, and intelligently respond to the disease environment
to release therapeutic agents (1).
Chemotherapy for the treatment of cancer refers to the use
of chemotherapeutical agents to disrupt the normal function-
ing of a cell by inducing apoptosis or preventing replication.
The limitations of conventional chemotherapeutic agents are
mainly due to their nonspecific distribution in the body where
they affect both cancerous and normal cells, thereby reducing
the achievable dose within the tumor tissues and causing ex-
cessive toxicities to normal cells. Moreover, cancer cells can
develop a resistance to the cytotoxicity not only of convention-
al chemotherapeutics but also of newer molecularly targeted
therapeutics (2).
The development of controlled release technology and
targeted drug delivery may result in a more efficient and less
harmful solution to overcome the limitations found in conven-
tional chemotherapy. Recent studies have been focused on
developing nanoscale delivery vehicles capable of controlling
the release of chemotherapeutic agents directly inside cancer
cells (3,4). Micellar structures are well suited to drug delivery
applications for multiple reasons. Their diameters are gener-
ally less than 100 nm, permitting them to extravasate through
the fenestrations in tumor vessels (1,5–7). The fenestration size
varies depending on the type of tumor e.g. for malignant brain
tumors it ranges from 7 to 100 nm, however for peripheral
tumors it ranges from 200 nm to 1.2 μm (5). Large pore cut off
sizes (~700 nm) were reported for breast cancer models (8).
Moreover, the hydrophilic surfaces of micellar structures
based on amphiphiles comprising PEG may shield them from
immediate recognition by the reticuloendothelial system
(RES) leading to an increase in their circulation time (9).
The core of the micellar structure can load hydrophobic drugs
which are protected by the hydrophilic corona during trans-
port to the tumor site (10). Many micellar formulations are
currently under clinical evaluation for the treatment of cancer
(e.g. doxorubicin loaded micelles, paclitaxel loaded polymeric
micelles and epirubicin loaded micelles (11–14)).
Previous studies on micellar like nanoparticles (NPs) for
drug targeting, have focused mainly on the self-assembly of
linear di- or tri-block amphiphilic copolymers into structures
with a hydrophobic core and a hydrophilic exterior (15,16).
Such NPs have been based on a range of polymers of different
hydrophobicity such as poly(lactic acid) (PLA), poly (amine-
esters) (PAE), poly(ε-caprolactone) (PCL), and poly(lactide-co-
glycolide) PLGA linked to a hydrophilic counterpart, especial-
ly PEG (15,17–21). However, although stable in solution, such
NP structures based on linear copolymers in general suffer
from low encapsulation efficiency and difficulty in controlling
polymer degradation (22).
During the last decade, the synthesis of more complicated
grafted, star-shaped, Y-shaped and dumbbell-shaped or den-
dritic copolymer structures containing three or more hydro-
philic arms emerging from the polymer center have been
carried out and the copolymers used for production of self-
assembling NPs for targeted drug delivery (4,23–25).
The copolymers used in these studies have most often been
based on PLA or PLGA but star-shaped block copolymers
based on PCL have also been produced (26,27).
NPs produced from star-shaped structures have been re-
ported to have superior properties, e.g. in overcoming the
thermodynamic instability of in the blood stream, showing
better loading capabilities, as compared to NPs produced
from linear di- or tri-block copolymers (26,28–30).
Moreover star-shaped polymers showed higher host–guest in-
teractions with small drug molecules when compared to linear
analogues (31). However, systematic comparisons between
NPs made from copolymers with different topologies and
physicochemical characteristics have only rarely been
reported (25) and very little has been reported in this regard
on PCL.
It has been shown that the in vivo circulation time of NPs
made from block-copolymers by the nanoprecipitation meth-
od (also used in the present work) is dependent on a range of
factors related to the physicochemical characteristics of the
copolymer (32). Hence, it was found that the circulation time
was inversely dependent on the molecular weight of the hy-
drophobic block, directly dependent on the log P of the hy-
drophobic block and the molecular weight of the PEG chain.
Further, it was shown that crystallization of the hydrophobic
block disrupts the PEG surface coverage and hence may in-
fluence the NP circulation time.
PCL is a biodegradable polyester with a hydrophobic part
in its backbone that degrade very slowly under hydrolytic
conditions in the human body. It has been shown to have a
log P between 11 and 12 for molecular weights between 3 and
9 kDa, respectively (32). In comparison, PLGA (50/50)
showed a log P between 2 and 4 for molecular weights be-
tween 5 and 8 kDa and PLA showed a log P between 7 and 11
for molecular weights between 3 and 10 kDa. Hence, PCL has
a superior hydrophobicity to PLGA and PLA. It has further
been shown that the crystallinity of PCL increases with in-
crease in molecular weight (32). Block copolymer of PEG with
PCL are expected to enhance the hydrophilicity of NP, pre-
vent opsonization, and phagocytosis by the RES system due to
steric stabilization created by PEG on the surface (33,34). It
was therefore of interest to investigate the physicochemical
properties, cytotoxicity, acute toxicity and pharmacokinetics
of NPs made from PCL of different molecular weight and
different copolymer structures, including di-, tri-block, star
shaped and dumbbell shaped copolymers, to include their
interaction with and release of a model cancer drug
noscapine.
Noscapine (NOS) is a phthalide isoquinoline alkaloid de-
rived from opium. It has been used as an oral antitussive agent
and has shown minimal toxic effects in animals and humans.
However, it was found to have a tubulin-binding activity and
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currently is undergoing clinical trials for anticancer therapy
(35). Although NOS has many advantages, such as higher
solubility in acidic medium (favored release near cancer tis-
sues) and resistance free anticancer properties, it has also sev-
eral limitations like other cancer chemotherapeutic drugs.
These limitations include: (a) hydrophobicity and limited sol-
ubility in an aqueous phase (36); (b) lack of selectivity, as most
anticancer drugs, which may cause significant damage to rap-
idly proliferating normal cells (35); (c) low oral bioavailability
(about 31%) both in humans and mice (37); (d) short plasma
half-life of below 2 h, which makes the design of controlled
release formulations difficult (36); (f) rapid elimination from
body tissues, hence, multiple injections are required for suc-
cessive chemotherapy (38). In addition, the selective release of
NOS as an alkaloid in the acidic medium of cancer tissue
would increase its safety and efficacy during use in anti-
cancer therapies.
The aim of the work carried out in this paper was to eval-
uate, in a systematic study, the effect of different factors such as
molecular weight of PCL, the PCL-PEG copolymer structure
(di-, tri-block, star-shaped or dumbbell-shaped), the CMC
and the polymer to drug ratio on the resultant NP size, zeta
potential, drug loading and entrapment efficiencies. From this
work the most promising structures will be selected and fur-
ther characterized in terms of atomic force microscopy, col-
loidal stability, cytotoxic activity, acute toxicity, hematological
and histopathological toxicity in rats and pharmacokinetics of
the NOS in order to fully understand the importance of the
different variables on the suitability of the PCL-PEG struc-
tures for drug targeting of cancer drug. In addition, the selec-
tive release of NOS will be evaluated in vitro at different pH
values to mimic the release in the blood stream and in cancer-
ous tissues.
MATERIALS AND METHODS
Materials
mPEG 1.9 and PEG 2 kDa were purchased from Polysciences
(Eppelheim, Germany). Stannous-2-ethyl-hexanoate and ε-
caprolactone were purchased from Sigma-Aldrich (Milan,
Italy). Noscapine (NOS) was a gift sample from EIPICO
Pharmaceutical Company (El Asher of Ramadan, Egypt).
Acetone, methanol, disodium hydrogen phosphate dihydrate,
and potassium dihydrogen phosphate were purchased fromEl
Nasr Pharmaceutical Company (Cairo, Egypt). Chloroform,
dichloromethane (DCM), acetonitrile, tetrahydrofuran
(THF), deuterated chloroform (CDCl3), and diethyl ether
were purchased from Thermo Fisher scientific Inc.
(Massachusetts, USA).
Fetal Bovine Serum (FBS), penicillin-streptomycin, trypsin-
EDTA, Tris–HCl, and RPMI 1640 medium were purchased
from Lonza (New Jersy, USA). Sulphorhodamine-B, trichlo-
roacetic acid, Leishman’s stain, dialysis membrane, hematox-
ylin and eosin were purchased from Sigma-Aldrich (St. Louis,
USA). HPLC internal standard papaverine was obtained
from Recordati (Milan, Italy). Muscovite mica discs were pur-
chased from Agar Scientific (Stansted, UK).
Methods
Synthesis and Characterizations of Block Copolymers
Synthesis of block copolymers (i.e. mPEG-PCL, PCL-PEG-
PCL, 4-armed PEG-PCL and 6-armed PEG-PCL) (Fig. 1)
was done by the ring opening polymerization method as pre-
viously described (4,26,30,31). The characteristics of the syn-
thesized polymers are given in Table 1. Characterization of
synthesized block copolymers was done using H1-NMR and
GPC analysis (supplementary information). Volume fraction
of PEG (f PEG) was calculated using Mn (NMR) and the den-
sities of bulk polymers (density of PEG=1.13 g cm −3, density
of PCL=1.25 g cm −3) using the following equation (Eq. 1)
(36):
fPEG ¼
the mass of PEG
the density of PEG
the mass of PEG
the density of PEG
þ the mass of PCL
the density of PCL
ð1Þ
Preparation of NOS Loaded Polymeric NPs
NPs were prepared using the nanoprecipitation method pre-
viously described by Fessi et al. (37). The polymer and NOS in
different ratios (10:1, 5:1 and 2.5:1) were accurately weighed
and dissolved in acetone (1 mL). The organic phase was added
dropwise to deionized water (10 ml) and stirred magnetically
at 1000 rpm until complete evaporation of acetone. A list of
the nanoparticles prepared from the polymers described in
Table 1 is given in Table 2. The produced nanoparticles were
centrifuged at 15,000 rpm for 30min then washed twice using
deionized water and frozen to −52°C before application of
vacuum (0.05 mBar) to freeze dry them using (Laboratory
Freeze Drier Alpha 1–4, Martin Christ, Germany).
Characterization of the Prepared NPs
Particle Size and Zeta Potential Determinations. Dynamic light
scattering (DLS) was used to measure average particle diam-
eter (Z-average) and polydispersity index (PDI) of the pre-
pared NPs in deionized water, while electrophoretic mobility
was used to measure zeta potential employing a Zetasizer
Nano ZS (Malvern Instruments Ltd., UK) equipped with
4 mW 633 nm He-Ne lasers. Samples were diluted
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appropriately using deionized water then samples were equil-
ibrated at 25°C in the device sample holder and analyses were
performed with the laser fixed at an angle of 173°. Data were
obtained and expressed as the average of at least 12 runs and
shown as the mean value± standard deviation of at least three
measurements.
Determination of Loading and Encapsulation Efficiency.NPs were
purified by centrifugation twice at 15,000 rpm for 30 min
(Cooling centrifuge, Hermle, Germany), the supernatant was
discarded then the sediment was washed using deionized wa-
ter and freeze dried (Laboratory Freeze Drier Alpha 1–4,
Martin Christ, Germany). NOS entrapment efficiency in the
NPs was assessed by dissolving a specific weight of NPs in a
mixture of chloroform and methanol (1:9) then the NOS con-
centration was determined at 291 nm in the organic solution
using UV spectroscopy (Shimadzu 1650PC, Tokyo, Japan).
The loading efficiency (DL%) and entrapment efficiency
(EE%) was obtained using the following equation (Eq. 2)
(38,39):
DL %ð Þ ¼ Drug loaded
Drug loaded þ polymer  100 ð2Þ
EE %ð Þ ¼ Actual drug loading
Theoretical drug loading
 100 ð3Þ
Critical Micelle Concentration (CMC) Assay. CMC values of P1-
6 micelles were determined with a spectroflurometric tech-
nique using pyrene as the fluorescence probe (40). For CMC
measurement, micellar dispersions loaded with pyrene were
prepared by adding 12 μL solution of pyrene in ethanol
(0.1 mg/mL) to 20 mL vials then leaving ethanol to evaporate
for 1 h. 10 mL of different concentrations (0.01–20 mg/L) of
the prepared polymer solution was added into the specified
vial, keeping the pyrene concentration in the vial solution to
be 1.2×10−4 mg/mL. The stoppered vials were heated for 3 h
at 65°C to equilibrate pyrene and the formed micelles were
Fig. 1 Different architecture of poly(ethylene glycol) (Red colored) and
poly(caprolactone) (Blue colored) block copolymers.
Table 1 The Molecular Weights and Volume Fraction of PEG of Block Co-polymers Used in the Preparation of Nanoparticles
Code Polymer Molecular weight (g mol −1) Mw/Mn (GPC) f PEG
(NMR)
CMC
(mg/L)
Mwt (NMR) PCL block (NMR) Mn (GPC)
P1 mPEG1.9 kDa-PCL 3154 1254 3520 1.7 0.63 7.08
P2 mPEG1.9 kDa-PCL 5662 3762 5953 1.9 0.36 5.62
P3 PCL-PEG2.0 kDa-PCL 5150 1575 5391 1.6 0.41 4.90
P4 PCL-PEG2.0 kDa-PCL 8263 3132 8677 2.4 0.26 1.26
P5 4 Arms PEG10kDa -(PCL)4 20,348 2587 21,852 1.8 0.52 0.49
P6 6Arms PEG17kDa -(PCL)6 33,230 2705 41,717 1.5 0.54 1.58
Mwt the Molecular weight of polymer
Mw Weight-average molecular weight
Mn Number-average molecular weight
Mw/Mn Poly dispersity index
f PEG Volume fraction of PEG
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allowed to cool overnight to room temperature. The
spectroflurometric measurement was done at excitation wave-
length of 334 nm, and emissions were recorded at wavelengths
I1=369 and I3=383 nm at slit widths for both excitation and
emission at 3 nm. Log values of polymer concentration were
plotted versus I1/I3 to get CMC values.
Atomic Force Microscopy (AFM). Mica discs were fixed in me-
tallic discs then cleaved many times with double-sided adhe-
sive tape then used as substrates. NPs were prepared by
nanoprecipitation in DI water then washed with the same
vehicle twice by centrifugation to remove excess polymer.
Samples were prepared by adding 10 μL of NPs (0.01 mg/
mL) to freshly cleaved muscovite mica. After 30 s, excess NPs
dispersions were removed and samples were washed with 2×
200 μL DI water. Samples were dried by exposing the mica
discs to dry filtered air for ~5 min before being imaged in air
(Atomic forcemicroscope, Veeco Instruments, Santa Barbara,
USA).
A Multimode AFM, equipped with E type scanner and
NanoScope IIIa controller, was used throughout this study.
The cantilevers used for imaging in air were silicon tapping
probes (OMCL-AC160TS, Olympus) with a spring constant
of 40–52 N/m operating at resonant frequencies of approxi-
mately 250–300 kHz. All imaging were conducted in tapping
mode in air at 512×512 pixel resolution, with scan speeds of
0.5–1 Hz (41). Topographical images were plane-flattened
and analyzed by the computer software Nanoscope Software
v 7.3.
In-Vitro Release of NOS from NPs
A certain volume of NPs dispersion containing an amount
equivalent to 100 μg of NOS was diluted to a final volume
of 2 mL in deionized water then transferred to a dialysis bag
with a molecular weight cut-off 11 kDa. Release studies were
done at two pH values in PBS buffer (pH 7.4 and pH 4.5), to
simulate the pH of the environment faced by the NPs in the
blood and the drop in pH to which NPs will be subjected in
the tumor cells, respectively. Dialysis bags were kept in 25 mL
of buffer within closed containers and shaken at 150 rpm using
a shaking water bath at 37±0.5°C (Thermostatically con-
trolled shaking water bath, GFL, Germany) (42,43). Samples
of 0.5 mL were withdrawn from the release medium at 0.25,
0.5, 1, 2, 3, 4, 6 and 8 h and replaced with fresh release
medium. NOS concentration was then determined using high
performance liquid chromatography (HPLC) (Agilent, USA).
HPLC separation was done using the method specified by
Chollet et al. at 35°C (44).
Colloidal Stability Studies
The colloidal stability of NPs was determined by measuring
their resistance to sodium sulfate induced aggregation (45).
NPs were prepared as described before and 1 mL of the pre-
pared nanoparticle dispersions (0.2%w/v in DI water) was
added to 1 mL of sodium sulfate solution of different concen-
trations to reach the desired sodium sulfate molarity at a poly-
mer concentration of 1 mg/mL. The turbidity of the formed
Table 2 Particle Size, Poly Dispersity Index (PDI) and Zeta Potential of Prepared Nanoparticles
NPs Polymer:drug ratio Size± SD PDI± SD Zeta± SD EE%±SD DL%±SD
NOS-P1 10:1 89.79±4.12* 0.442±0.027 −15.50±0.46 20.20±2.78* 1.84±0.25
5:1 93.16±9.18* 0.415±0.061 −19.30±2.25 12.86±1.96 2.14±0.33
2.5:1 131.23±21.63 0.38±0.043 −19.87±0.50 13.62±1.99 3.89±0.57
NOS-P2 10:1 173.15±3.18* 0.61±0.103 −11.88±9.79 37.61±1.61* 3.42±0.15
5:1 201.27±5.80* 0.732±0.007 −11.17±0.67 25.62±6.11* 4.27±1.02
2.5:1 245.97±18.85 0.470±0.069 −12.43±6.52 15.18±1.97 4.34±0.56
NOS-P3 10:1 275.70±6.08 0.50±0.167 −10.94±1.36 29.74±15.95 2.7±1.54
5:1 387.97±5.71* 0.513±0.135 −11.63±1.51 42.10±2.19 7.02±0.37
2.5:1 261.43±48.75 0.690±0.141 −11.15±2.09 24.87±3.17 7.11±0.91
NOS-P4 10:1 65.61±6.53* 0.45±0.054 −17.55±1.48 34.64±4.09* 3.15±0.37
5:1 83.53±8.3* 0.24±0.031 −17.93±2.29 28.90±3.45* 4.82±0.58
2.5:1 178.35±44.34 0.448±0.240 −25±7.35 19.44±3.56 5.55±1.02
NOS-P5 10:1 137.07±7.50* 0.420±0.036 −9.43±7.61 0.81±0.2 0.07±0.02
5:1 128.95±1.77* 0.35±0.037 −8.16±5.15 5.65±0.07 0.94±0.01
2.5:1 154.90±6.69 0.37±0.026 −12.95±0.49 7.11±6.06 2.03±1.73
NOS-P6 10:1 782.40±64.21* 0.74±0.050 −6.83±1.20 91.96±1.54* 8.36±0.14
5:1 876.75±18.17* 0.79±0.018 −5.82±0.49 65.71±3.15* 10.95±0.53
2.5:1 306.27±48.01 0.464±0.077 −7.67±2.48 2.28±0.74 0.65±0.21
*P<0.05 compared with ratio (2.5:1)
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dispersions was measured spectrophotometrically (UV/VIS
spectrophotometer, Jenway, UK) after 10 min at 500 nm
and the critical coagulation concentration (CCC) was deter-
mined as the concentration at which a significant increase in
turbidity was noticed using a plot of sodium sulfate concen-
tration versus turbidity value.
Cytotoxic Activity Assays
The cytotoxicities of NOS solution, NOS-P1 and NOS-P4
NPs (Table 2) were determined using the sulphorhodamine-
B (SRB) method and monolayers of MCF-7 human breast
cancer cells (46,47). The cancer cells were grown in RPMI-
1640 medium, containing 10% heat inactivated FBS, 50
units/mL of penicillin and 50 mg/mL of streptomycin. Cells
were maintained at 37°C in a humidified atmosphere contain-
ing 5% CO2. Serial subculturing was used to maintain the
cells as a Bmonolayer cultures^.
Cells were collected by 0.25% Trypsin-EDTA and seeded
in 96-well plates at a density of 1–2×103 cells/well in a me-
dium supplemented with RPMI-1640. After 24 h, various
concentrations (0.1–1000 μmol/l of NOS and equivalent
amounts of NOS in NPs) were added to each well and cells
were incubated for 72 h. After 72 h treatment, 10% trichlo-
roacetic acid was added and left for 1 h at 4°C for fixation of
cells followed by staining of the treated wells for 10 min at
room temperature using 0.4% SRB dissolved in 1% acetic
acid. The plates were air dried for 24 h then Tris–HCl was
added and the plates were left shaken at 1600 rpm for 5min to
solubilize the dye. The optical density (OD) of each well was
measured spectrophotometrically at 564 nm using an ELISA
microplate reader (ELISA microplate reader, ChroMate-
4300, FL, USA). The inhibitory concentration of 50% (IC50)
values were determined according to the equation for
Boltzman sigmoidal concentration–response curve using the
nonlinear regression fitting models (Graph Pad, Prism
Version 5).
Pharmacokinetic Studies on NOS Loaded NPs
The protocol for these studies was reviewed and approved by
the research ethics committee of Faculty of Pharmacy, Ain
Shams University, Cairo, Egypt. All glasswares used for pre-
paring solutions and NPs were sterilized by autoclaving, and
the entire preparation procedures were carried out in a lam-
inar flow hood under aseptic conditions. Ninety femaleWistar
albino rats (120–160 g) were divided into three groups, each
comprising 30 rats. The different groups were as follow:
Group 1 received i.v. NOS- P1 NPs, Group 2 received i.v.
NOS- P4 NPs, Group 3 received i.v. NOS solution (in dilute
HCL) (48). NOS and the equivalent amount of NOS-NPs
were administered for all animals in a dose of 50 mg/kg in a
volume of 1 mL. Intravenous administration was done
through the peripheral tail vein of the rat. At different time
intervals 0.083, 0.167, 0.25, 0.5, 1, 2, 4, 6, 8, and 12 h follow-
ing administration of NOS or NPs, blood samples were
collected from 3 rats through the retro-orbital vein
using heparinized Helmington microcapillary tubes into
polypropylene microcentrifuge tubes containing 25 μL
of 20 mM sodium citrate, centrifuged at 4600 rpm for
15 min and the separated plasma samples were stored
at −80°C until analyzed (42). Acetonitrile was added to
the thawed plasma samples for protein precipitation and
extraction of NOS (49).
The mixture was vortexed for 5 min (Vortex mixer, IKA
MS3 Digital, Wilmington, Germany) to extract both free
NOS and NP bound, then centrifuged at 3000 rpm for
10 min (cooling centrifuge, Hermle, Germany), and finally
filtered through a 0.45 μm membrane filter. Samples of
50 μl were injected into the HPLC apparatus for analysis
(Agilent HPLC, USA). HPLC assay was performed by mod-
ification of the method specified by Chollet et al. at 40°C using
papaverine as internal standard (44).
Plasma concentration data were analyzed using PKSolver
Excel Add-in (50). The mean (free and NP bound) NOS con-
centrations in plasma were plotted against time. Then the
following pharmacokinetic parameters were assessed: The
maximum plasma concentration Cmax (ng/mL), the half-life
t1/2 (h), the area under NOS concentration-time curve up to
the last sampling point AUC0–12 (ng/mL h), the area under
NOS concentration-time curve with extrapolation to infenity
AUCinf (ng/mL h), and the mean residence time MRT (h).
The area under the curve was calculated by the linear trape-
zoidal rule up to the last sampling point (AUC0–12) with ex-
trapolation to infinity (AUCinf).
Toxicity Studies
Determination ofmaximum tolerated dose and the lethal dose
50% (LD50) of NOS solution and NOS- P1 NPs was carried
out as specified byMoura et al. (51). Twenty femaleWister rats
in groups of 5 were intravenously injected via the tail vein
following a dose-escalation schedule based on three dose levels
of NOS as solution and NOS- P1 NPs (50, 100, and 200 mg
NOS/kg as a single-dose) and saline was administered to a
group of 5 rats as a control. These concentrations were select-
ed as NOS is well known to have LD50 in mice of 83
±6.1 mg/kg (48). Animals were observed until day 7 for any
death occurrence and body weights were measured every
2 days to determine the maximum tolerated dose (defined as
the dose that causes approximately 15% loss in body weight
and does not result in lethality) and the lethal dose of 50%
(LD50) that is defined as the administered dose which causes
death of 50% of the animals, determined by interpolation of
results (death percentage in the group/dose).
Shalaby et al.
Hematological Toxicity
Twenty-four hours after the injection of a single 200 mg/kg
dose of NOS as solution, NOS-P1 NPs and saline into female
Wistar rats, blood samples were withdrawn by retro-orbital
sinus puncture using heparinized Helmington microcapillary
tubes. Hematological toxicity was determined from the data of
hematology parameters which include erythrocytes count,
platelets, leukocytes and leukocytes differential count by using
blood cell counter (Cell Dyn 1700, Abbott, USA) (52). Blood
smears were prepared as soon as possible after blood collec-
tion on a glass slide and quickly dried and stained with
Leishman’s stain for the differential blood count.
Histopathological Analysis
At the end of the observation period (7 days) of treatment of
the rats with NOS, NOS-P1 NPs (Toxicity studies, 2.2.8) and
the saline control groups, selective organs (liver, kidney,
spleen, brain, heart and lung) were dissected out. Organs were
formalin-fixed and embedded in paraffin then sectioned into
5 μm sections and stained with Hematoxylin and Eosin
(H&E). Microscopic evaluation was done by a pathologist
(Light microscope, Carl Zeiss Axiostar Plus, Göttingen,
Germany).
Statistical Analysis
All data were expressed as mean± standard deviation (SD).
Comparison of the mean values was undertaken using
ANOVA test followed by Tukey post-Hoc test for multiple
comparisons with SPSS statistical software program, USA.
p<0.05 were considered statistically significant.
RESULTS AND DISCUSSION
Characterization of Block Copolymers
Block copolymers were efficiently prepared by ring opening
polymerization of different molecular weights of PCL blocks
using mPEG 1.9 kDa and PEG 2.0 kDa as starting materials
respectively. 1H-NMR spectra (Figure S1) of the prepared
block co-polymers were produced, which showed the charac-
teristic peaks of PCL at 1.40 ppm (β-methine (CH) proton,
quintet split; Figures S1–S2 (d)), 1.64 ppm (γ and δ-methine
(CH) proton, quintet split; Figures S1–S2 (c,b)), 2.28 ppm (α-
methine (CH) proton, triplet split; Figures S1–S2 (e)) and
4.04 ppm (ε-methine (CH) proton, triplet split; Figures S1–
S2 (a)) and the characteristics peak of PEG at 3.65 ppm (meth-
ylene (CH2) protons, triplet split; Figures S1–S2 (f)). The mo-
lecular weights of the block co-polymers (Table 1) were calcu-
lated using integration of 1H-NMR chromatograms as well as
GPC. The CMC of the P1-6 micelles was determined by a
florescence technique using pyrene as a probe (Table 1). It can
be observed that the CMC values of the polymers were in the
range (0.48–7.08 mg/L) and it can be noticed that for either
di- or triblock copolymers, CMC values decreased as the mo-
lecular weight of the hydrophobic part (PCL) increased.
Unexpectedly, P5 and P6 showed low values of CMC when
compared to other polymers with higher hydrophilicity (P1).
Although P5 and P6 had high hydrophilicity as indicated by
their high f PEG values, they showed low CMC values which
may be due to the higher density of PCL blocks per molecule
(4 and 6 respectively) which render the aggregation process
much easier. This would suggest that the star shaped polymers
due to their architecture can produce more stable micelles
that can resist dilution after injection compared to linear
polymer (53).
Characterization of Prepared NPs
Particle Size, Zeta Potential and Entrapment Efficiency
Determinations
Table 2 shows the particle size of NPs produced from different
block co-polymers with different polymer to drug ratios as well
as their zeta potentials and entrapment efficiencies. Particle
sizes were in the range from 65.61 to 876.75 nm, zeta poten-
tials were in the range from−5.82 to−25mV and entrapment
efficiencies were in the range from 2.28 to 91.96%. Particle
size was used to select the most suitable NPs for further inves-
tigations. P5 and P6 were excluded from selection as their NPs
showed either a very low entrapment efficiency (NOS-P5) or a
large particle size (NOS-P6) and both are not suitable for
cancer drug delivery (37). Polymer configuration of P6 may
be the main determinant for NP stability and size as the poly-
mer will be more restricted to localized spots on the NP sur-
face rather than covering the whole NP surface (Fig. 1)
allowing non-shielded areas to interact and form large sized
NP aggregate. Statistical analysis showed that in most NPs the
ratio 2.5:1 had particle sizes that were significantly higher than
that of the ratios 5:1 and 10:1 (p<0.05). Meanwhile, there
were no significant differences between the particle sizes of
NPs obtained from ratios 5:1 and 10:1. The ratio 5:1 was
selected as the preferred ratio since it in general produced
smaller particles than the 2.5:1 ratio and a particle size equiv-
alent to those produced using the ratio 10:1 with a lower
polymer amount. This together with steric stabilization and
hydrophilicity contributes to their decreased uptake by the
RES (9,54–56).
Regarding the zeta potential, all tested NPs were found to
have negative values that ranged from −5.82 to −25 mV.
NOS-P1 and P4 showed significantly (p<0.05) higher charge
values when compared to NPs with the same polymer to drug
ratios, however, NOS-P5 and P6 showed the lowest values of
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zeta potential. Although P5 and P6 have high fPEG values
compared to P2-P4 and hence lower surface charge (−5 to
−12 mV). With exception of NOS-P1, it can be noticed that
particles prepared using polymers with high fPEG have sur-
faces with low negativity (NOS-P3, 5 and 6), however those
with low fPEG have surfaces are more negative (NOS-P4) (57).
Due to their small size and considerable entrapment effi-
ciency at polymer to drug ratio (5:1), NOS containing NPs
(NOS-P1 and NOS-P4) were selected for further investiga-
tions as their size and PEG coated surfaces made them good
candidates as delivery systems for cancer treatment.
Atomic Force Microscopy (AFM)
From the data above two different NOS loaded nanoparticle
systems (NOS-P1 and NOS-P4) at polymer to drug ratio (5:1)
were selected for further investigation. Figure 2 shows the
AFM images of these NOS loaded NPs (NOS-P1 and NOS-
P4) with recorded particle diameters of 165.6 and 132.13 nm
and heights of 44.9 and 18.79 nm, respectively, as determined
by section analysis (Fig. 2). The sizes obtained by AFM were
found to be larger than those obtained by DLS. This could be
due to the nature of the micellar like particles, which are soft
and easily deform under the force applied during AFM imag-
ing. It was described by Roos et al., that nanoparticles can
suffer from nanoindentation followed by particle expansion
during AFM imaging (58), when imaged using the tapping
mode, thereby being suppressed with the highly resonating
tips of the device against the mica substrate resulting in an
increase in particle size and decrease in particle height. This
was especially the case when using cantilevers with a high
spring constant value (K=40-50 N/m). It is worth to say that
in the present study, it was not possible to use the contact
mode for AFM imaging since the NPs were too soft and ad-
hered and changed the shape of the imaging AFM tips while
scanning the samples, thus producing very low quality images.
Zhang et al. using DSCmeasurement showed that similar copol-
ymers exhibited low glass transition temperatures suggesting that
nanoparticles formed with these materials would be soft and
deformable at body temperature. Hence these nanoparticles
would bemore capable of surviving splenic filtration and passing
through cancer tissue fenestration than rigid ones (59).
In-Vitro Release of NOS from NPs
Figure 3 shows the release patterns of NOS from the NPs
(NOS-P1 and NOS-P4) with polymer to drug ratio (5:1) at
pH values of 7.4 and 4.5. It was found that NOS release was
significantly higher and faster (after 15 min) at pH 4.5 when
compared to pH 7.4 (p<0.05). A similar behavior was previ-
ously reported for release of NOS and other basic drugs from
polymeric nanoparticles when tested at acidic conditions
(34,42,60). It is to be noted that after 1 h the more hydrophilic
NOS-P1 showed significantly higher release rates compared
to that of NOS-P4 prepared using polymer with low fPEG
value. After 8 h, NPs at pH 7.4 released only 25.44 and
36.3% of their NOS load, while at pH 4.5, 85.7 and 99.7%
of the drug fromNOS-P4 andNOS-P1 respectively. The high
release rates of NOS in acidic pH is expected because of its
basic nature which suggest high drug solubility at low pH
values and hence higher release rates from polymeric NPs
(34,60,61). This drug release characteristics will allow the
NPs to continue carrying the bulk of NOS while circulating
in the blood and releasing their load majorly in the tumor
tissue due to its lower pH (62). This should lead to a significant
increase in therapeutic effect of NOS and prevention of drug
losses if widely distributed within the body.
It was also observed from Fig. 3 that NOS-P1 showed the
highest release profile compared to NOS-P4 at either pH
values. This may be attributed to the low molecular weight
of polymer P1 compared to P4, combined with P1 being com-
posed of only two polymer blocks that hence would be
Fig. 2 AFM image of nanoparticles
formed from: (a) NOS-P1 at
polymer to drug ratio (5:1). (b)
NOS-P4 at polymer to drug ratio
(5:1).
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expected to form only weak Van der Waals interaction with
NOS. Accordingly, NOS more easily escaped from the less
dense matrix of NOS-P1 NPs as compared to that of the other
NP formulation composed of a block-copolymer of higher
molecular weight (triblock co-polymer chain) and hydropho-
bicity (Table 1).
Colloidal Stability Studies
As shown in Fig. 4, the selected types of NPs showed different
degrees of stability whenmixed with increasing concentrations
of sodium sulfate. NOS-P1 showed the highest critical coagu-
lation concentration (CCC=0.5 M) indicating its high stabil-
ity against electrolytes. NOS-P4 NPs showed a reasonable,
but less stable behavior against increasing sodium sulfate con-
centration, (i.e. CCC=0.3 M). This can be explained by the
degree of effective hydration of the NPs by the water sheath
and steric stabilization, which depends on the amount, length
and freedom of movement of the PEG on the surface of the
particles. P1 comprises the greatest amount of PEG
(fPEG=0.63) compared to P4 (fPEG=0.26) (Table 1).
Although NOS-P1 and P4 NPs showed no significant dif-
ference in measured zeta potential at all tested polymer to
drug ratios the difference in measured CCC values could be
interpreted based on polymer conformation on the NP sur-
face. P1 is a di-block-copolymer consisting of a hydrophilic
PEG chain attached to a single PCL block and hence PEG
will be freely protruding on the surface of the micellar type
nanoparticle. Such a conformation would be more stable to
the charge neutralizing effect of sodium sulfate than particles
made of tri-block-copolymers, where the PEG is attached in
both ends to PCL blocks (P4) and would be expected to form
flower like NPs with PEG in loop confirmation on its surface
and with less freedom of movement (63). The flower like con-
formation of PEG chains would allow the exposure of more
hydrophobic PCL areas that would easier allow the process of
NOS- P4 NPs aggregation.
Hence, the NPs produced from the P1 polymer express the
highest colloidal stability which results suggest that the NPs
tested here will not aggregate in blood, which contribute to
their safety when clinically administered.
Cell Cytotoxicity
The cytotoxicity profiles of NOS solution, NOS-P1 and
NOS-P4 NPs were examined using the SRB assay to evaluate
their effect on MCF-7 cell line survival (Fig. 5). Cytotoxicity
analysis indicated that the IC50 value of NOS-P1 NPs was
equivalent to 6.916 μmol/l respectively, which were signifi-
cantly lower than that of NOS-P4 NPs (38.92 μmol/l), as well
as NOS solution (41.11 μmol/l) (P<0.05). The difference in
cytotoxicity may be due to the higher release of NOS from
NOS-P1 NPs compared to NOS-P4 NPs when in an acidic
medium.
A cytotoxicity assay for polymers (P1 and P4) was also done
and we found that the polymers had little or no cytotoxic effect
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on the cells (data not shown). The above mentioned results
indicate that the increased cytotoxic effect of the NOS NPs
compared to NOS solution could be due to a combination of
the small particle size of the NPs resulting in increased uptake
into the cells and the selective increased acidic pH release of
NOS-P1.
Pharmacokinetic Studies on NOS and Selected
NOS-NPs
Figure 6 shows the mean NOS concentrations in plasma in
rats after i.v. administration of NOS-P1, NOS-P4 NPs (poly-
mer to drug ratio (5:1)) and NOS solution and the correspond-
ing pharmacokinetic parameters are shown in Table 3. It
should be noted that since the HPLC method extracts NOS
from the plasma samples, not only free NOS but also NOS
from the NP will be extracted, and hence the plasma concen-
trations given are a combination of free and NP bound NOS.
It was found that the NOS solution showed the highest
plasma concentration (Cmax) compared to both NPs investi-
gated (NOS-P1 and NOS-P4). Both NPs released NOS in the
blood at low concentrations as supported by the in-vitro release
test at pH 7.4 (Fig. 3). It should also be noted that both NP
systems showed an initial high plasma concentration of NOS
followed by an abrupt decrease. This may be due to desorp-
tion of NOS from the surface of NPs followed by rapid distri-
bution and uptake of the drug into different organs as previ-
ously described by other research groups (13,64).
The biodistribution of NPs in different organs of the body,
especially the liver and spleen, after IV injection, is mainly
controlled by interaction with the RES and can to some de-
gree be modified by the size and the surface characteristics,
such as hydrophilicity and steric stabilization, of the nanopar-
ticles. The more hydrophobic the NPs are and the lower the
amount of PEG that exists on their surfaces, the faster they
become opsonized and removed by the RES system. On the
contrary, high coverage of NPs surfaces with PEG and a high
degree of steric stabilization decreases their opsonization and
uptake by the RES system (42,65). The selected NPs have the
value of fPEG in the following order NOS-P1>NOSP4
(Table 1). Furthermore, as discussed above the NOS-P1 NPs
are expected to show a high degree of steric stabilization with
a resultant low RES capture and a long blood circulation
time.Moreover, NOS as a hydrophobic drug can be adsorbed
to the hydrophobic moieties of the copolymer in the NPs.
NOS-P4 showed the highest initial concentration of NOS at
5 min (P<0.05), compared to NOS-P1, which may be attrib-
uted to the moderate amount of PEG on the surfaces which
would allow most of the hydrophobic drug, NOS, to be
adsorbed on the surface in-between the PEG chains. When
the NPs entered the blood stream the drug molecules
desorbed in the plasma resulting in a high initial concentra-
tion, followed by a sudden drop in plasma levels due to
opsonization and uptake by the RES system. NOS-P1 NPs,
comprising the highest amount of PEG (Table 1), showed a
moderate level of NOS concentration in plasma which was
maintained for longer time than the NOS solution and the
NOS-P4. It was also noticed, that the NOS solution showed a
biphasic elimination profile as previously reported by Gibaldi
andWeiner (66). They hypothesized that NOS is rapidly elim-
inated from plasma compartment while being stored in adi-
pose tissue from which it is eliminated at a lower rate
imparting NOS its biphasic elimination. Upon observation
of NOS NPs, it was found that the hydrophilic property of
NPs reduced their deposition into adipose tissue, which result-
ed in reduction of the biphasic elimination of NOS as shown
in Fig. 6.
These results were supported by the pharmacokinetic pa-
rameters shown in Table 3. MRT and t1/2 of NOS-P1 NPs
was significantly higher than that of NOS solution (p<0.05).
AUC0–12 and AUC0-inf are indicators of availability of NOS
in the injected delivery system. NOS solution showed higher
AUC0–12 thanNOS-P4NPs but not higher than that of NOS-
P1 NPs and this finding was expected from the soluble form of
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the drug. On the contrary, NOS-P1 had the highest AUC0-inf
compared to NOS solution and NOS-P4. This is thought to
be due to the higher density of PEG chains on the surface of
NOS-P1 which imparted a stealth property and for them
resulting in longer half-life and longer blood circulating prop-
erty (67,68).
The present results indicate that the incorporation of NOS
in NOS-P1 NPs resulted in an increased half-life and hence
availability of NOS to cancer tissue. The increase in NOS
concentration in the blood after administration of NOS-P1
compared to NOS control solution may exceed the bioavail-
ability of NOS injection in the soluble form and increase the
duration and effect of the injected dose of NOS.
Toxicity Studies
When comparing the different tested nanoparticle formula-
tions, NOS-P1 NPs showed the highest in-vitro drug release
profile, the longest circulation time and the lowest IC50 of
the selected NPs. Hence, NOS-P1 NPs was selected for fur-
ther investigation of in vivo toxicity to various tissues in rats.
Upon observing the rats for 7 days, there were no deaths
recorded among the rats used in this experiment during the
test period after the administration of 50, 100 and 200 mg/kg
of NOS and the equivalent concentrations of NOS-P1 in
nanoparticles. In addition, no significant weight loss
(P<0.05) exceeding 15% of the initial body weight was ob-
served in the rats with both drug solution and nanoparticles
(Fig. 7a and b). Hence, it was not possible to determine the
lethal dose or the maximum tolerated dose from this experi-
ment. Higher doses of NOS could only be administered by
increasing the solution volume to non-injectable values.
The cytotoxicity assay showed that NOS-P1 NPs was able
to kill cancer cells at a much lower concentration than a NOS
solution. In the simple toxicity study, it was further found that
NOS-P1 was safe for normal cells of the body. This test indi-
cated the safety of using these NPs clinically for cancer treat-
ment especially if efficiently targeted to cancer tissues.
Hematological Toxicity
The results of our previous toxicity studies were supported by
testing the hematological toxicity of NOS solution and NOS-
P1 NPs at 200 mg/Kg NOS in rats. After measuring hema-
tology parameters from rats injected with NOS, NOS-P1 NPs
and saline, there was no significant difference (p<0.05) ob-
served in the blood cell counts between different groups as
shown in Fig. 8. The results of this test together with that of
Table 3 Pharmacokinetic
Parameters of NOS in Rat Plasma
After i.v. Injection of Nanoparticles
(NOS-P1 and NOS-P4) with
Polymer to Drug Ratio (5:1) and
NOS Solution
Parameter Mean± SD
Group 1 (NOS-P1) Group 2 (NOS-P4) Group 3 (NOS)
Cmax (ng/mL) 2055.97±98.89* 3152.49±84.99* 3642.28±100.71
T1/2 (hr) 22.92±9.2* 15.98±5.21 5.12±3.02
MRT (hr) 32.4± 12.93* 15.52±3.65 5.31±0.42
AUC0–12 (ng/mL*hr) 9351.74±1970.57 2358.67±759.85* 7308.96±2116.77
AUC0-inf (ng/mL*hr) 28365.57±2799.95* 3959.34±1520.79 8317.39±2300.66
Cmax: the maximum plasma concentration (ng/mL), t1/2: the half-life (h), AUC0-12: the area under NOS
concentration-time curve up to the last sampling point (ng/mL h), AUC0-inf: the area under NOS concentration-time
curve with extrapolation to infinity (ng/mL h), and MRT: the mean residence time (h)
*P<0.05 compared with NOS solution
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colloidal stability study gives us a good indication about the
safety of using of these formulation in clinical trials. In a sim-
ilar study using doxorubicin loaded HA-PEG-PCL NPs, it
was found that incorporating the anticancer drug in the NPs
improved its haemocompatability (69).
Histopathological Analysis
The histopathological analysis showed that a single treatment
with NOS solution and NOS-P1 NPs (200 mg/kg NOS) did
not result in any detectable pathological abnormalities in rats.
Metastatic lesions were completely absent in the liver, brain,
heart, kidneys, lungs and spleen in both NOS solution and
NOS-P1 NPs treated groups (Fig. 9).
CONCLUSIONS
A series of PEG/PCL block copolymers were synthesized
using ring opening polymerization and used to formulate
nanozised drug delivery systems.
Combining data of zeta potential and particle sizes, we
found that increasing the number of polymer PEG blocks in
the polymers (NOS-P5, NOS-P6) used for NP preparation
resulted in a decrease in surface charge but was associated
with increased NP size and the probability of NP aggregation.
The NP with the highest fPEG produced from the linear PCL-
PEG was shown to have the smallest particle size and a high
degree of stability to high concentrations of sodium sulfate.
The NPs produced using the polymer to drug ratio (10:1
and 5:1) were of a size significantly smaller than polymer to
drug ratio (2.5:1). As there was no significant difference be-
tween the sizes of NPs produced at polymer to drug ratio 10:1
and 5:1, we decided to use the ratio with the least amount of
polymer. Among tested polymers, P1 and P4 were selected for
further investigations due to the small size of NOS loaded NPs
when produced at polymer to drug ratio (5:1) (<100 nm).
AFM imaging revealed that the particles were nearly
spherical in shape and of small size. Release profiles of NOS
loaded NPs (NOS-P1 and NOS-P4) with polymer to drug
ratio (5:1 at pH 4.5) were significantly higher and faster than
those obtained at pH 7.4. These results indicated that the NPs
will continue carrying most of its content of NOS while circu-
lating in the blood, however they will release its load at the
acidic extracellular environment of tumor tissue. Moreover,
NOS-P1 NPs showed the highest extent in vitro drug release
compared to NOS-P4. These results suggested a similar high
stability of these NPs when injected to blood intravenously.
MCF-7 cell line cytotoxicity analysis showed that the for-
mulation of NOS into NPs resulted in a dramatic increase in
its cytotoxic activity most likely due to a combined effect of the
small particle size and the selective NOS release (69–71). In
addition, the NOS-P1 plasma profile was found to have a long
half-life and MRT with a high values of AUC0–12 and AUC0-
inf indicating a higher availability for reaching potential tumor
tissues.
On the other hand, injection of NOS solution and NPs into
rats did not result in any deaths or weight loss among the
groups of rats used. Therefore, it wasn’t possible to determine
either the maximum tolerated dose or the LD50. Moreover,
toxicity of NOS solution and nanoparticle formulations on
normal cells was evaluated by determination of their
Fig. 8 Haematological toxicity of NOS solution and NOS-P1 nanoparticles. (a) erythrocytes count, (b) Platelets count, (c) Leucocytes count, and (d) Differential
leucocytes count. LYMPH: lymphocytes, MID: the mid-cell fraction (eosinophils, basophils, monocytes, and precursors of WBCs), GRAN: granulocytes
(p< 0.005).
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hematological and histopathological toxicity. Hematology pa-
rameters and sections of different organ tissues showed no
abnormality when compared to control group. So, it can be
concluded that (at least in vitro) NOS loaded biodegradable
NPs has increased NOS potency against cancer cells and
in vivo enhanced its bioavailability and blood circulation time.
This could be of great benefit to cancer patients by po-
tentially enabling a reduction in the dose administered
and eliminating the need for frequent injections of the
drug. However caution needs to be taken into account
when extrapolating to the human situation from in vitro
and rat results.
Fig. 9 Light photomicrograph
showing H&E- stained 10-μm-thick
sections of liver (×200), brain
(×200), heart (×200), lung
(×200), kidney (×200), spleen
(×100) from groups of rats ((a)
Control, (b) NOS-P1 nanoparticles
and (c) NOS solution). No
histopathological differences were
noted in these tissues.
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